Children's Zyrtec Hives Relief Patent Expiration

Children's Zyrtec Hives Relief is a drug owned by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 02, 2018. Details of Children's Zyrtec Hives Relief's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6455533 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Jul, 2018

(6 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Children's Zyrtec Hives Relief is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Children's Zyrtec Hives Relief's family patents as well as insights into ongoing legal events on those patents.

Children's Zyrtec Hives Relief's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Children's Zyrtec Hives Relief's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 02, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Children's Zyrtec Hives Relief Generics:

There are no approved generic versions for Children's Zyrtec Hives Relief as of now.

How can I launch a generic of Children's Zyrtec Hives Relief before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Children's Zyrtec Hives Relief's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Children's Zyrtec Hives Relief's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Children's Zyrtec Hives Relief -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
5 mg and 10 mg 25 Mar, 2005





About Children's Zyrtec Hives Relief

Children'S Zyrtec Hives Relief is a drug owned by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div. It is used for managing symptoms of seasonal and perennial allergic rhinitis. Children'S Zyrtec Hives Relief uses Cetirizine Hydrochloride as an active ingredient. Children'S Zyrtec Hives Relief was launched by J And J Consumer Inc in 2020.

Approval Date:

Children's Zyrtec Hives Relief was approved by FDA for market use on 30 November, 2020.

Active Ingredient:

Children's Zyrtec Hives Relief uses Cetirizine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cetirizine Hydrochloride ingredient

Treatment:

Children's Zyrtec Hives Relief is used for managing symptoms of seasonal and perennial allergic rhinitis.

Dosage:

Children's Zyrtec Hives Relief is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, CHEWABLE Discontinued ORAL
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, CHEWABLE Discontinued ORAL